Related Experiment Videos
Intractable epilepsies. An open trial with Clobazam
Acta Neurologica
|February 1, 1989
Summary
Clobazam (clobazam) showed initial effectiveness in reducing seizures for intractable epilepsies, but tolerance developed over time. Intermittent use may be a viable strategy for these patients.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Intractable epilepsies often require adjunctive therapies.
- Clobazam is a benzodiazepine used as an add-on treatment for epilepsy.
Purpose of the Study:
- To evaluate the efficacy and tolerance of Clobazam as an add-on treatment in patients with intractable epilepsies.
Main Methods:
- A cohort of 28 patients with intractable epilepsies, most with associated handicaps, received Clobazam as add-on therapy.
- Seizure frequency was monitored over a six-month period.
Main Results:
- Initial significant seizure reduction was observed: 73% for partial seizures and 62% for generalized tonic-clonic seizures (GTCs) within 2-3 months.
- Tolerance developed, with seizure reduction decreasing to 36% for partial seizures and 39% for GTCs by month six.
- Four patients (14%) achieved seizure freedom by month six.
Conclusions:
- Clobazam demonstrates initial efficacy but tolerance can limit long-term effectiveness in intractable epilepsies.
- The development of tolerance suggests that intermittent Clobazam administration might be a beneficial approach for selected patients.